Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Shanghai Pancreatic Cancer Institute; Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China ∗Corresponding author.
E-mail addresses: yuxianjun@fudanpci.org , yuxianjun@fudan.edu.cn (X.-J. Yu)
Abstract：Pancreatic adenocarcinoma is the fifth leading cause of cancerrelated deaths worldwide, and this incidence is projected to increase further in future decades [1] . Furthermore, despite years of attempting to improve treatment for patients with pancreatic adenocarcinoma, the 5-year overall survival rate remains low at < 7% [2] . Thus, this cancer is devastating, and effective treatment strategies are desperately needed. Although the available diagnosis and treatment measures do not significantly improve patient outcomes, several years of hard work have revolutionized the field using new concepts from medical oncology and produced several scientific advances in the diagnosis and treatment of pancreatic adenocarcinoma.
. [J]. Hepatobiliary Pancreat Dis Int, 2018, 17(5): 383-384.
Wang WQ, Liu L, Ni QX, Yu XJ. Guidelines for the diagnosis and treatment of pancreatic adenocarcinoma (2018 edition): A standardized procedure recommended in China. Hepatobiliary Pancreat Dis Int, 2018, 17(5): 383-384.
2018, Vol. 17 
